Alivus Life Sciences Posts Q1 Revenue of ₹6.4 Billion

MUMBAI, July 30, 2026 — Active Pharmaceutical Ingredient (API) manufacturer Alivus Life Sciences Limited reported its financial results for the first quarter ending June 30, 2026 (Q1 FY27) on Thursday, July 30, 2026. According to financial disclosures submitted to domestic stock exchanges, the company logged revenue from operations of ₹6.4 billion (₹640.41 crore) during the three-month period. Alivus Life Sciences posted a quarterly net profit after tax (PAT) of ₹1.6 billion (₹160.08 crore), representing a 31.8 percent year-over-year increase in profitability. The performance highlights operational efficiency, expanding global sales across non-GPL (Glenmark Pharmaceuticals) segments, and favorable product mix realizations.

Operating Performance and Margin Expansion

The top-line revenue of ₹6.4 billion was driven by expanded demand across core active pharmaceutical ingredients in chronic therapeutic categories, including cardiovascular, central nervous system (CNS), pain management, and anti-diabetic treatments. The company's strategic focus on expanding its independent commercial customer base led to a 26.5 percent year-over-year growth in non-GPL revenue.

Operating profit (EBITDA) reached ₹2.34 billion (₹234.10 crore), pushing EBITDA margins to 36.6 percent. Margin expansion of 650 basis points year-over-year was supported by input cost rationalization, improved manufacturing leverage at its primary production sites, and high-capacity utilization across its API manufacturing lines.

Balance Sheet Position and CDMO Pipeline

Alivus Life Sciences maintained its net debt-free financial position through the June quarter, generating ₹901 million (₹90.10 crore) in free cash flows. Total cash and bank balances stood at ₹8.80 billion (₹880.20 crore) at the end of the quarter.

In addition to core API production, the company is advancing its Contract Development and Manufacturing Operations (CDMO) portfolio. Ongoing capital expenditure projects including the construction and operationalization of its high-capacity API manufacturing complex in Solapur, Maharashtra are positioned to support long-term commercial scale and international supply agreements.

Official Sources Section

According to official financial statements filed by Alivus Life Sciences Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Q1 FY27 results were reviewed by the Audit Committee and approved by the Board of Directors on July 30, 2026. Disclosures were formally submitted to BSE Limited and the National Stock Exchange of India. Regulatory oversight remains under the Securities and Exchange Board of India (SEBI).

Quote Section

"According to officials and corporate filings submitted to stock exchanges, the first-quarter performance reflects high operating leverage, driven by steady growth in the non-GPL business and disciplined raw material management across core API manufacturing operations."

Why It Matters

Alivus Life Sciences' Q1 FY27 financial results provide a key performance gauge for India's active pharmaceutical ingredient manufacturing sector. For pharmaceutical supply chains, institutional investors, and global healthcare partners, sustained margin expansion and robust cash generation demonstrate resilient operational execution amid global drug supply chain realignments.

Key Facts at a Glance

• Quarterly Revenue: Alivus Life Sciences registered Q1 FY27 revenue from operations of ₹6.4 billion.

• Profit Growth: Net profit after tax expanded 31.8 percent year-over-year to reach ₹1.6 billion.

• Margin Record: Operating EBITDA margins reached a record 36.6 percent.

• Debt Position: Company continues to operate as a net debt-free entity with ₹8.80 billion in cash reserves.

Frequently Asked Questions (FAQs)

What was Alivus Life Sciences' revenue for the June quarter?

Alivus Life Sciences recorded revenue from operations of ₹6.4 billion (₹640.41 crore) for the quarter ending June 30, 2026.

How much net profit did the company deliver in Q1 FY27?

The company reported a post-tax net profit of ₹1.6 billion (₹160.08 crore) for the April–June quarter, up 31.8 percent from ₹121.54 crore in Q1 FY26.

What driven the EBITDA margin expansion in Q1 FY27?

EBITDA margins expanded to 36.6 percent due to a favorable product mix, rationalized raw material input costs, and a 26.5 percent growth in high-margin non-GPL business segments.

Where can investors verify official financial filings for Alivus Life Sciences?

Official financial disclosures and stock exchange announcements are accessible on the web portals of BSE Limited, the National Stock Exchange of India, and Alivus Life Sciences Limited.

Source: BSE Limited, National Stock Exchange of India, Alivus Life Sciences Limited, Securities and Exchange Board of India